TY - JOUR AU - Kastritis, E. AU - Dimopoulos, M. A. PY - 2007 DA - 2007// TI - The evolving role of lenalidomide in the treatment of hematologic malignancies JO - Expert Opin Pharmacother VL - 8 UR - https://doi.org/10.1517/14656566.8.4.497 DO - 10.1517/14656566.8.4.497 ID - Kastritis2007 ER - TY - JOUR AU - Mitsiades, C. S. AU - Mitsiades, N. PY - 2004 DA - 2004// TI - CC-5013 (Celgene) JO - Curr Opin Investig Drugs VL - 5 ID - Mitsiades2004 ER - TY - JOUR AU - Tariman, J. D. PY - 2007 DA - 2007// TI - Lenalidomide: a new agent for patients with relapsed or refractory multiple myeloma JO - Clin J Oncol Nursing VL - 11 UR - https://doi.org/10.1188/07.CJON.569-574 DO - 10.1188/07.CJON.569-574 ID - Tariman2007 ER - TY - JOUR AU - Sonneveld, P. AU - Palumbo, A. PY - 2008 DA - 2008// TI - Lenalidomide: a new therapy for multiple myeloma JO - EJHPP VL - 14 ID - Sonneveld2008 ER - TY - JOUR AU - Shah, S. R. AU - Tran, T. M. PY - 2007 DA - 2007// TI - Lenalidomide in myelodysplastic syndrome and multiple myeloma JO - Drugs VL - 67 UR - https://doi.org/10.2165/00003495-200767130-00005 DO - 10.2165/00003495-200767130-00005 ID - Shah2007 ER - TY - JOUR AU - Falco, P. AU - Cavallo, F. AU - Larocca, A. AU - Liberati, A. M. AU - Musto, P. AU - Boccadoro, M. AU - Palumbo, A. PY - 2008 DA - 2008// TI - Lenalidomide and its role in the management of multiple myeloma JO - Expert Rev Anticancer Ther VL - 8 UR - https://doi.org/10.1586/14737140.8.6.865 DO - 10.1586/14737140.8.6.865 ID - Falco2008 ER - TY - JOUR AU - Hideshima, T. AU - Richardson, P. G. AU - Anderson, K. C. PY - 2006 DA - 2006// TI - Current therapeutic uses of lenalidomide in multiple myeloma JO - Expert Opin Invest Drugs VL - 15 UR - https://doi.org/10.1517/13543784.15.2.171 DO - 10.1517/13543784.15.2.171 ID - Hideshima2006 ER - TY - JOUR AU - Corral, L. G. AU - Haslett, P. A. AU - Muller, G. W. AU - Chen, R. AU - Wong, L. M. AU - Ocampo, C. J. AU - Patterson, R. T. AU - Stirling, D. I. AU - Kaplan, G. PY - 1999 DA - 1999// TI - Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha JO - J Immunol VL - 163 ID - Corral1999 ER - TY - JOUR AU - Anderson, K. C. PY - 2005 DA - 2005// TI - Lenalidomide and thalidomide: mechanisms of action-similarities and differences JO - Seminars Hematol VL - 42 UR - https://doi.org/10.1053/j.seminhematol.2005.10.001 DO - 10.1053/j.seminhematol.2005.10.001 ID - Anderson2005 ER - TY - JOUR AU - Richardson, P. AU - Anderson, K. PY - 2004 DA - 2004// TI - Immunomodulatory analogs of thalidomide: an emerging new therapy in myeloma JO - J Clin Oncol VL - 22 UR - https://doi.org/10.1200/JCO.2004.05.984 DO - 10.1200/JCO.2004.05.984 ID - Richardson2004 ER - TY - JOUR AU - Verhelle, D. AU - Corral, L. G. AU - Wong, K. AU - Mueller, J. H. AU - Parseval, L. M. AU - Pergakes, K. J. AU - Schafer, P. H. AU - Chen, R. AU - Glezer, E. AU - Ferguson, G. D. AU - Lopez-Girona, A. AU - Muller, G. W. AU - Brady, H. A. AU - Chan, K. W. H. PY - 2007 DA - 2007// TI - Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells JO - Cancer Res VL - 67 UR - https://doi.org/10.1158/0008-5472.CAN-06-2317 DO - 10.1158/0008-5472.CAN-06-2317 ID - Verhelle2007 ER - TY - STD TI - Revlimid (lenalidomide) [Full Prescribing Information]. 2012, Summit, NJ: Celgene Corporation, [http://www.revlimid.com/pdf/REVLIMID_PI.pdf] UR - http://www.revlimid.com/pdf/REVLIMID_PI.pdf ID - ref12 ER - TY - JOUR AU - Richardson, P. G. AU - Schlossman, R. L. AU - Weller, E. PY - 2002 DA - 2002// TI - Immunomodulatory drug CC 5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma JO - Blood VL - 100 UR - https://doi.org/10.1182/blood-2002-03-0996 DO - 10.1182/blood-2002-03-0996 ID - Richardson2002 ER - TY - JOUR AU - Sastry, B. S. AU - Gananadhamu, S. AU - Prasad, S. V. S. AU - Venu, G. R. K. PY - 2009 DA - 2009// TI - New spectrophotometric methods for estimation of lenalidomide in pharmaceutical formulations JO - Int J PharmTech Res VL - 1 ID - Sastry2009 ER - TY - JOUR AU - Darwish, I. A. AU - Khalil, N. Y. AU - Bakheit, A. H. AU - Alzoman, N. Z. PY - 2012 DA - 2012// TI - A highly sensitive fluorimetric method for determination of lenalidomide in its bulk form and capsules via derivatization with fluorescamine JO - Chem Cent J VL - 6 UR - https://doi.org/10.1186/1752-153X-6-118 DO - 10.1186/1752-153X-6-118 ID - Darwish2012 ER - TY - JOUR AU - Saravanan, G. AU - Rao, B. M. AU - Ravikumar, M. AU - Suryanarayana, M. V. AU - Someswararao, N. AU - Acharyulu, P. V. R. PY - 2007 DA - 2007// TI - Development of an HPLC assay method for lenalidomide JO - Chromatographia VL - 66 UR - https://doi.org/10.1365/s10337-007-0290-y DO - 10.1365/s10337-007-0290-y ID - Saravanan2007 ER - TY - JOUR AU - Maheswara, R. L. AU - Janardhan, R. K. AU - Bhaskar, R. L. AU - Raveendra Reddy, P. PY - 2012 DA - 2012// TI - Development of a rapid and sensitive HPLC assay method for lenalidomide capsules and its related substances JO - E-J Chem VL - 9 UR - https://doi.org/10.1155/2012/673736 DO - 10.1155/2012/673736 ID - Maheswara2012 ER - TY - JOUR AU - Tohnya, T. M. AU - Hwang, K. AU - Lepper, E. R. PY - 2004 DA - 2004// TI - Determination of CC-5013, an analogue of thalidomide, in human plasma by liquid chromatographymass spectrometry JO - J Chromatogr B Analyt Technol Biomed Life Sci VL - 811 UR - https://doi.org/10.1016/S1570-0232(04)00666-X DO - 10.1016/S1570-0232(04)00666-X ID - Tohnya2004 ER - TY - JOUR AU - Liu, Q. AU - Farley, K. L. AU - Johnson, A. J. AU - Muthusamy, N. AU - Hofmeister, C. C. AU - Blum, K. A. AU - Schaaf, L. J. AU - Grever, M. R. AU - Byrd, J. C. AU - Dalton, J. T. AU - Phelps, M. A. PY - 2008 DA - 2008// TI - Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma JO - Ther Drug Monit VL - 5 UR - https://doi.org/10.1097/FTD.0b013e318185813d DO - 10.1097/FTD.0b013e318185813d ID - Liu2008 ER - TY - BOOK PY - 2001 DA - 2001// TI - Guidance for Industry on Bioanalytical Method Validation PB - Department of Health and Human Services CY - Rockville, MD ID - ref20 ER - TY - STD TI - European Medicines Agency: guideline on bioanalytical method validation. [http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf] UR - http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf ID - ref21 ER -